This Gastroparesis Drugs market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.
The gastroparesis drugs market size has grown strongly in recent years. It will grow from $5.39 billion in 2024 to $5.73 billion in 2025 at a compound annual growth rate (CAGR) of 6.3%. The growth in the historic period can be attributed to side effects of existing treatments, gastrointestinal motility research, clinical need, patient advocacy, and regulatory support.
The gastroparesis drugs market size is expected to see strong growth in the next few years. It will grow to $7.2 billion in 2029 at a compound annual growth rate (CAGR) of 5.9%. The growth in the forecast period can be attributed to the increasing prevalence of diabetes, the aging population, rising awareness and diagnosis rates, increase in healthcare expenditure, and government and private funding. Major trends in the forecast period include advancements in gastroenterology, improved diagnostic techniques, technological innovations, research funding, and collaborative research efforts.
The growing prevalence of diabetes is expected to drive the expansion of the gastroparesis drugs market. Diabetes is a chronic condition characterized by elevated blood sugar levels due to insufficient insulin production or the body's inability to effectively use insulin. The rise in diabetes cases is attributed to factors such as sedentary lifestyles, poor dietary habits, genetic predisposition, urbanization, aging populations, limited healthcare access, and increasing obesity rates globally. Gastroparesis drugs are commonly prescribed to diabetic patients to alleviate symptoms such as nausea, vomiting, and delayed gastric emptying - gastrointestinal issues that are frequent complications of diabetes. These medications aim to improve gastric motility and enhance the quality of life for those with diabetes-related gastroparesis. For example, in March 2024, according to the Office for Health Improvement & Disparities, a UK-based government department, between March 2022 and March 2023, the percentage of individuals with type 1 diabetes receiving all eight recommended care processes increased by 22%, while for type 2 diabetes, the increase was 21%. Additionally, the percentage of individuals achieving target HbA1c levels rose to 37.9%, the highest ever reported by the National Diabetes Audit (NDA). Therefore, the rising prevalence of diabetes is contributing to the growth of the gastroparesis drugs market.
Major players in the gastroparesis drugs sector are directing their efforts towards introducing innovative medications, such as the Gimoti (metoclopramide) nasal spray, to enhance their market competitiveness. Gimoti (metoclopramide) nasal spray is a pharmaceutical designed to alleviate symptoms of gastroparesis in adults, fostering stomach emptying by bolstering gastrointestinal motility. By circumventing the gastrointestinal tract, it is absorbed directly into the bloodstream via the nasal mucosa. For example, in April 2022, Evoke Pharma Inc., a pharmaceutical company based in the United States, disclosed that the U.S. Food and Drug Administration (FDA) had granted GIMOTI (metoclopramide) nasal spray new drug product exclusivity. This exclusivity affords Evoke exclusive marketing privileges for three years following the initial approval date, as per the Hatch-Waxman Act, shielding the product from generic competition.
In June 2022, Eagle Pharmaceuticals Inc., a pharmaceutical firm headquartered in the United States, completed the acquisition of Acacia Pharma Group plc for $102 million (€94.7 million). Through this acquisition, Eagle Pharmaceuticals intends to broaden its range of offerings by integrating Acacia's FDA-approved hospital products, BARHEMSYS and BYFAVO, which cater to unmet clinical demands in acute care environments. Acacia Pharma Group plc, based in the United Kingdom, specializes in providing antiemetic medications utilized in gastroparesis treatment.
Major companies operating in the gastroparesis drugs market are Pfizer Inc., AbbVie Inc., Bayer AG, Sanofi SA., AstraZeneca plc, Abbott Laboratories, GSK plc, Takeda Pharmaceutical Inc., Teva Pharmaceutical Inc., Otsuka Pharmaceutical Co. Ltd., Bausch Health Companies Inc., Eisai Co. Ltd., Evoke Pharma Inc., Cadila Pharmaceuticals, Cipla Ltd., Neurogastrx Inc., Ipca Laboratories Ltd., ANI Pharmaceuticals Inc., Salix Pharmaceuticals Inc., Vanda Pharmaceuticals Inc., Theravance Biopharma Inc, Rhythm Pharmaceuticals Inc., Processa Pharmaceuticals Inc., Aclipse Therapeutics LLC, ETX Pharma Inc.
North America was the largest region in the gastroparesis drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastroparesis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the gastroparesis drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Gastroparesis drugs are medications utilized to handle and address gastroparesis, a condition characterized by delayed emptying of the stomach, leading to symptoms such as nausea, vomiting, and abdominal discomfort. Typically, these medications consist of prokinetics to enhance stomach motility, antiemetics to regulate nausea and vomiting, and drugs to alleviate pain and other associated symptoms.
The primary categories of gastroparesis drugs consist of over-the-counter (OTC) medications and prescription drugs. Over-the-counter (OTC) drugs are those available for purchase without a prescription from a healthcare provider. These medications are utilized for treating various forms of gastroparesis, including diabetic gastroparesis, post-surgical gastroparesis, idiopathic gastroparesis, among others, and are administered through various routes such as oral ingestion, injection, and others. They encompass various types of drugs such as prokinetic agents, antiemetics, proton pump inhibitors, among others, which are distributed through hospitals, pharmacies, clinics, and online platforms.
The gastroparesis drugs market research report is one of a series of new reports that provides gastroparesis drugs market statistics, including gastroparesis drugs industry global market size, regional shares, competitors with a gastroparesis drugs market share, detailed gastroparesis drugs market segments, market trends and opportunities, and any further data you may need to thrive in the gastroparesis drugs industry. This gastroparesis drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The gastroparesis drugs market consists of sales of ondansetron, metoclopramide, amitriptyline, and erythromycin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The gastroparesis drugs market size has grown strongly in recent years. It will grow from $5.39 billion in 2024 to $5.73 billion in 2025 at a compound annual growth rate (CAGR) of 6.3%. The growth in the historic period can be attributed to side effects of existing treatments, gastrointestinal motility research, clinical need, patient advocacy, and regulatory support.
The gastroparesis drugs market size is expected to see strong growth in the next few years. It will grow to $7.2 billion in 2029 at a compound annual growth rate (CAGR) of 5.9%. The growth in the forecast period can be attributed to the increasing prevalence of diabetes, the aging population, rising awareness and diagnosis rates, increase in healthcare expenditure, and government and private funding. Major trends in the forecast period include advancements in gastroenterology, improved diagnostic techniques, technological innovations, research funding, and collaborative research efforts.
The growing prevalence of diabetes is expected to drive the expansion of the gastroparesis drugs market. Diabetes is a chronic condition characterized by elevated blood sugar levels due to insufficient insulin production or the body's inability to effectively use insulin. The rise in diabetes cases is attributed to factors such as sedentary lifestyles, poor dietary habits, genetic predisposition, urbanization, aging populations, limited healthcare access, and increasing obesity rates globally. Gastroparesis drugs are commonly prescribed to diabetic patients to alleviate symptoms such as nausea, vomiting, and delayed gastric emptying - gastrointestinal issues that are frequent complications of diabetes. These medications aim to improve gastric motility and enhance the quality of life for those with diabetes-related gastroparesis. For example, in March 2024, according to the Office for Health Improvement & Disparities, a UK-based government department, between March 2022 and March 2023, the percentage of individuals with type 1 diabetes receiving all eight recommended care processes increased by 22%, while for type 2 diabetes, the increase was 21%. Additionally, the percentage of individuals achieving target HbA1c levels rose to 37.9%, the highest ever reported by the National Diabetes Audit (NDA). Therefore, the rising prevalence of diabetes is contributing to the growth of the gastroparesis drugs market.
Major players in the gastroparesis drugs sector are directing their efforts towards introducing innovative medications, such as the Gimoti (metoclopramide) nasal spray, to enhance their market competitiveness. Gimoti (metoclopramide) nasal spray is a pharmaceutical designed to alleviate symptoms of gastroparesis in adults, fostering stomach emptying by bolstering gastrointestinal motility. By circumventing the gastrointestinal tract, it is absorbed directly into the bloodstream via the nasal mucosa. For example, in April 2022, Evoke Pharma Inc., a pharmaceutical company based in the United States, disclosed that the U.S. Food and Drug Administration (FDA) had granted GIMOTI (metoclopramide) nasal spray new drug product exclusivity. This exclusivity affords Evoke exclusive marketing privileges for three years following the initial approval date, as per the Hatch-Waxman Act, shielding the product from generic competition.
In June 2022, Eagle Pharmaceuticals Inc., a pharmaceutical firm headquartered in the United States, completed the acquisition of Acacia Pharma Group plc for $102 million (€94.7 million). Through this acquisition, Eagle Pharmaceuticals intends to broaden its range of offerings by integrating Acacia's FDA-approved hospital products, BARHEMSYS and BYFAVO, which cater to unmet clinical demands in acute care environments. Acacia Pharma Group plc, based in the United Kingdom, specializes in providing antiemetic medications utilized in gastroparesis treatment.
Major companies operating in the gastroparesis drugs market are Pfizer Inc., AbbVie Inc., Bayer AG, Sanofi SA., AstraZeneca plc, Abbott Laboratories, GSK plc, Takeda Pharmaceutical Inc., Teva Pharmaceutical Inc., Otsuka Pharmaceutical Co. Ltd., Bausch Health Companies Inc., Eisai Co. Ltd., Evoke Pharma Inc., Cadila Pharmaceuticals, Cipla Ltd., Neurogastrx Inc., Ipca Laboratories Ltd., ANI Pharmaceuticals Inc., Salix Pharmaceuticals Inc., Vanda Pharmaceuticals Inc., Theravance Biopharma Inc, Rhythm Pharmaceuticals Inc., Processa Pharmaceuticals Inc., Aclipse Therapeutics LLC, ETX Pharma Inc.
North America was the largest region in the gastroparesis drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastroparesis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the gastroparesis drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Gastroparesis drugs are medications utilized to handle and address gastroparesis, a condition characterized by delayed emptying of the stomach, leading to symptoms such as nausea, vomiting, and abdominal discomfort. Typically, these medications consist of prokinetics to enhance stomach motility, antiemetics to regulate nausea and vomiting, and drugs to alleviate pain and other associated symptoms.
The primary categories of gastroparesis drugs consist of over-the-counter (OTC) medications and prescription drugs. Over-the-counter (OTC) drugs are those available for purchase without a prescription from a healthcare provider. These medications are utilized for treating various forms of gastroparesis, including diabetic gastroparesis, post-surgical gastroparesis, idiopathic gastroparesis, among others, and are administered through various routes such as oral ingestion, injection, and others. They encompass various types of drugs such as prokinetic agents, antiemetics, proton pump inhibitors, among others, which are distributed through hospitals, pharmacies, clinics, and online platforms.
The gastroparesis drugs market research report is one of a series of new reports that provides gastroparesis drugs market statistics, including gastroparesis drugs industry global market size, regional shares, competitors with a gastroparesis drugs market share, detailed gastroparesis drugs market segments, market trends and opportunities, and any further data you may need to thrive in the gastroparesis drugs industry. This gastroparesis drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The gastroparesis drugs market consists of sales of ondansetron, metoclopramide, amitriptyline, and erythromycin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Gastroparesis Drugs Market Characteristics3. Gastroparesis Drugs Market Trends and Strategies4. Gastroparesis Drugs Market - Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market32. Global Gastroparesis Drugs Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the Gastroparesis Drugs Market34. Recent Developments in the Gastroparesis Drugs Market
5. Global Gastroparesis Drugs Growth Analysis and Strategic Analysis Framework
6. Gastroparesis Drugs Market Segmentation
7. Gastroparesis Drugs Market Regional and Country Analysis
8. Asia-Pacific Gastroparesis Drugs Market
9. China Gastroparesis Drugs Market
10. India Gastroparesis Drugs Market
11. Japan Gastroparesis Drugs Market
12. Australia Gastroparesis Drugs Market
13. Indonesia Gastroparesis Drugs Market
14. South Korea Gastroparesis Drugs Market
15. Western Europe Gastroparesis Drugs Market
16. UK Gastroparesis Drugs Market
17. Germany Gastroparesis Drugs Market
18. France Gastroparesis Drugs Market
19. Italy Gastroparesis Drugs Market
20. Spain Gastroparesis Drugs Market
21. Eastern Europe Gastroparesis Drugs Market
22. Russia Gastroparesis Drugs Market
23. North America Gastroparesis Drugs Market
24. USA Gastroparesis Drugs Market
25. Canada Gastroparesis Drugs Market
26. South America Gastroparesis Drugs Market
27. Brazil Gastroparesis Drugs Market
28. Middle East Gastroparesis Drugs Market
29. Africa Gastroparesis Drugs Market
30. Gastroparesis Drugs Market Competitive Landscape and Company Profiles
31. Gastroparesis Drugs Market Other Major and Innovative Companies
35. Gastroparesis Drugs Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Gastroparesis Drugs Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on gastroparesis drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for gastroparesis drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The gastroparesis drugs market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include: the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Drug Type: Over-the-counter (OTC) Drugs; Prescription Drugs2) By Drug Class: Prokinetic Agents; Antiemetic Drugs; Proton Pump Inhibitors; Other Drug Classes
3) By Disease Type: Diabetic Gastroparesis; Post-Surgical Gastroparesis; Idiopathic Gastroparesis; Other Disease Types
4) By Route of Administration: Oral; Injectables; Other Routes of Administration
5) By Distribution Channel: Hospitals; Pharmacies; Clinics; E-commerce
Subsegments:
1) Over-the-counter (OTC) Drugs: Antacids; Anti-Nausea Medications; Antiemetics; Digestive Enzyme Supplements2) Prescription Drugs: Prokinetic Agents; Antiemetic Drugs; Antibiotics; Antidepressants
Key Companies Mentioned: Pfizer Inc.; AbbVie Inc.; Bayer AG; Sanofi SA.; AstraZeneca plc
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
The major companies featured in this Gastroparesis Drugs market report include:- Pfizer Inc.
- AbbVie Inc.
- Bayer AG
- Sanofi SA.
- AstraZeneca plc
- Abbott Laboratories
- GSK plc
- Takeda Pharmaceutical Inc.
- Teva Pharmaceutical Inc.
- Otsuka Pharmaceutical Co. Ltd.
- Bausch Health Companies Inc.
- Eisai Co. Ltd.
- Evoke Pharma Inc.
- Cadila Pharmaceuticals
- Cipla Ltd.
- Neurogastrx Inc.
- Ipca Laboratories Ltd.
- ANI Pharmaceuticals Inc.
- Salix Pharmaceuticals Inc.
- Vanda Pharmaceuticals Inc.
- Theravance Biopharma Inc
- Rhythm Pharmaceuticals Inc.
- Processa Pharmaceuticals Inc.
- Aclipse Therapeutics LLC
- ETX Pharma Inc.
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 200 |
Published | April 2025 |
Forecast Period | 2025 - 2029 |
Estimated Market Value ( USD | $ 5.73 Billion |
Forecasted Market Value ( USD | $ 7.2 Billion |
Compound Annual Growth Rate | 5.9% |
Regions Covered | Global |
No. of Companies Mentioned | 26 |